AntibodyPlus Meets AI

The Chinese Antibody Society will host the mAbTalk Symposium on the day following the 2023 Antibody Engineering & Therapeutics (AET) conference at the same location.

Post COVID-19 Pandemic: New Frontiers and Opportunities of Antibody-based Biologics

Post COVID-19 Pandemic: New Frontiers and Opportunities of Antibody-based Biologics

10/30/2022

AntibodyPlus: next generation antibody-based biologics

In the midst of the rapid development of novel antibody therapies and the “new normal” of the pandemic, the Chinese Antibody Society (CAS) will hold the 2022 Annual Conference in Boston on October 30, 2022 (Sunday). This will be the first in-person event of the Chinese Antibody Society since the pandemic started. The topic of the CAS 2022 Annual Conference is: “AntibodyPlus: next generation antibody-based biologics.”

05/22/2022

Emerging targets for immuno-oncology

TBD

10/16/2021

The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond

In our two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development.

05/23/2021

New Horizon of Antibody Drug Conjugate (ADC)

FREE Registration is now open for mAbTalks series in 2021 - “New Horizon of Antibody-Drug Conjugate (ADC)” virtual symposium. The symposium will be held online on May 23, 2021. In this half-day event, speakers from both industry and academia will share their insights in diverse topics of ADC-based therapeutics, including discovery & new techniques, clinical development.

12/05/2020

Revisit the Perspectives of Bispecific Antibodies under the COVID-19 Pandemic

Bispecific and multispecific antibody-based therapies are at the cutting-edge of therapeutic biologics development, and provide new opportunities to address unmet medical needs. In our one-day symposium, eight speakers from both industry and academia will share insights on all aspects of bispecific antibody-based therapeutic development, including novel targets and molecular formats, development of the lead candidate from discovery to clinics, CMC challenges and strategies, regulatory considerations, patent protection strategies, and COVID-19 related therapeutics.